Basilea Pharmaceutica AG Allschwil to Acquire the Rights to Fosmanogepix from Amplyx Pharmaceuticals Inc Call Transcript
Ladies and gentlemen, welcome to the Basilea Pharmaceutica Acquisition of Fosmanogepix Conference Call and Live Webcast. I am Sandra, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead, sir.
Thank you very much. Hello. I'm David Veitch, CEO of Basilea, and I'd like to welcome you to our conference call and webcast to discuss the acquisition of the broad spectrum antifungal, fosmanogepix, from Amplyx Pharmaceuticals, an affiliate of Pfizer, which we have reported this morning as an ad hoc announcement. The ad hoc release is available on our website at basilea.com.
I would also like to mention that this call contains forward-looking statements. Joining me on our call today are Dr. Marc Engelhardt, our Chief Medical Officer; and Adesh Kaul, our Chief Financial Officer.
Basilea is a leading
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
